Dietmar Schwab
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Bioequivalence Between a Gantenerumab Disposable Syringe and an Autoinjector: A Randomized Controlled Trial in Healthy Volunteers.
Journal: Clinical pharmacology in drug development
Published: November 28, 2025
A Baseline Score to Predict Response to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration.
Journal: Translational vision science & technology
Published: June 10, 2021
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
Journal: JAMA ophthalmology
Published: July 31, 2020
Ocular Half-Life of Intravitreal Biologics in Humans and Other Species: Meta-Analysis and Model-Based Prediction.
Journal: Molecular pharmaceutics
Published: December 27, 2019
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
Journal: Ophthalmology
Published: December 21, 2018
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
Journal: Drug research
Published: August 14, 2018
Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study.
Journal: BMJ open ophthalmology
Published: December 22, 2016
Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration.
Journal: Ophthalmology. Retina
Published: December 05, 2016
Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
Journal: Hypertension (Dallas, Tex. : 1979)
Published: April 28, 2016
A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
Journal: Molecular pharmaceutics
Published: January 05, 2016
Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: October 01, 2013
Last Updated: 09/26/2026